Loading...
XSHE
002422
Market cap9.21bUSD
Oct 09, Last price  
39.72CNY
1D
2.50%
1Q
-9.87%
Jan 2017
146.40%
IPO
11.26%
Name

Sichuan Kelun Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:002422 chart
P/E
37.13
P/S
3.44
EPS
1.07
Div yield, %
1.62%
Shrs. gr., 5y
2.15%
Rev. gr., 5y
2.19%
Revenues
18.35b
-15.87%
2,016,128,4312,601,689,9493,220,313,4374,026,399,9585,103,811,3655,885,278,6176,831,281,9818,023,421,2897,763,339,9828,565,943,41511,434,948,84116,351,790,23917,636,267,04416,464,201,27717,277,407,53319,038,216,00021,453,929,00021,812,414,00018,350,066,000
Net income
1.70b
-42.03%
216,288,383309,887,206427,851,436661,229,249966,126,0951,087,515,7481,079,521,5861,001,902,613645,271,323584,638,829748,544,1871,212,944,249937,855,128829,386,3361,102,554,3481,705,324,0002,456,112,0002,935,892,0001,701,935,000
CFO
2.81b
-37.40%
168,423,194221,075,877250,688,633149,292,039342,931,058402,771,4671,050,373,8451,218,735,9381,239,429,4361,725,407,4151,203,191,4022,953,506,9672,216,737,6392,219,381,5192,847,118,4283,127,457,0905,337,068,9314,492,861,8442,812,590,402
Dividend
May 11, 20260.468 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.

Key people

Gexin Liu
Chairman of the Board · since 2003
Degui Lai
Chief Financial Officer, Deputy General Manager · since 2014
Hao Feng
Deputy General Manager, Secretary of the Board · since 2014
Yihong Liao
Deputy General Manager · since 2022
Hongbo Tan
Deputy General Manager · since 2013
Juncai Wei
Deputy General Manager · since 2012
Zhonghua Wu
Deputy General Manager · since 2016
Junyou Ge
Director · since 2024
Director · since 2019
Sichuan Liu
General Manager, Director · since 2015
Xianxiang Zhou
Director · since 2024
Jinbo Gao
Independent Director · since 2021
Independent Director · since 2021
Fuqing Wang
Independent Director · since 2024
IPO date
Jun 03, 2010
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
成都市新都卫星城工业开发区南二路
成都市, SC 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT